Get the Stockscreener App
26.34
4.74%
-1.31
Amylyx Pharmaceuticals Inc stock is traded at $26.34, with a volume of 1.15M.
It is down -4.74% in the last 24 hours and down -19.28% over the past month.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
See More
Previous Close:
$27.65
Open:
$27.65
24h Volume:
1.15M
Relative Volume:
0.84
Market Cap:
$3.31B
Revenue:
$-665.00K
Net Income/Loss:
$-150.11M
P/E Ratio:
-17.48
EPS:
-1.5071
Net Cash Flow:
$-124.53M
1W Performance:
-6.40%
1M Performance:
-19.28%
6M Performance:
+48.56%
1Y Performance:
+73.63%
1-Day Range:
$26.20
$27.65
1-Week Range:
$26.20
$28.49
52-Week Range:
$10.83
$41.14
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Name
Amylyx Pharmaceuticals Inc
Sector
Phone
617-682-0917
Address
55 CAMBRIDGE PARKWAY, CAMBRIDGE
Compare AMLX vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
26.34 | 3.31B | -665.00K | -150.11M | -124.53M | -1.5071 |
TAK
Takeda Pharmaceutical Co Adr
|
19.67 | 62.84B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.50 | 48.40B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
10.13 | 44.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
79.38 | 32.80B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
533.12 | 22.87B | 3.17B | 1.29B | 1.01B | 27.09 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-03-26 | Initiated | Stifel | Buy |
| Jul-10-25 | Resumed | Goldman | Buy |
| Jun-24-25 | Initiated | Guggenheim | Buy |
| Jun-17-25 | Initiated | Citigroup | Buy |
| May-30-25 | Initiated | TD Cowen | Buy |
| Apr-07-25 | Upgrade | Mizuho | Neutral → Outperform |
| Nov-18-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-23-24 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-18-24 | Downgrade | Mizuho | Buy → Neutral |
| Mar-11-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-11-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-08-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-08-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Jul-24-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Jan-05-23 | Initiated | BofA Securities | Buy |
| May-25-22 | Initiated | Citigroup | Buy |
| Apr-01-22 | Downgrade | Goldman | Buy → Neutral |
View All
Amylyx Pharmaceuticals Inc Stock (AMLX) Latest News
A director proposes selling 100,000 shares of Amylyx Pharmaceuticals (AMLX). - Stock Titan
Amylyx Pharmaceuticals, Inc. (AMLX) Latest Stock News & Headlines - Yahoo! Finance Canada
Certain Restricted Stock Unit of Amylyx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 4-OCT-2026. - www.marketscreener.com
Certain Common Stock of Amylyx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 4-OCT-2026. - marketscreener.com
Amylyx Pharmaceuticals, Inc. (AMLX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum - Business Wire
Amylyx (NASDAQ: AMLX) co-CEO sells shares to cover taxes - Stock Titan
Automatic tax sale by Amylyx (NASDAQ: AMLX) CFO - Stock Titan
Automatic tax-share sale by Amylyx (AMLX) legal chief - Stock Titan
Amylyx Pharmaceuticals (AMLX) co-CEO sells shares to cover tax bill - Stock Titan
Amylyx (AMLX) CMO auto-sells 10,028 shares for taxes - Stock Titan
Amylyx Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Automatic stock sale for taxes ahead at Amylyx Pharmaceuticals (AMLX) - Stock Titan
Amylyx (NASDAQ: AMLX) insider schedules automatic 60K-share sale - Stock Titan
Amylyx (NASDAQ: AMLX) officer lines up tax-driven share sale - Stock Titan
Amylyx (AMLX) insider schedules automatic tax share sale - Stock Titan
Automatic Amylyx (AMLX) stock sale set to cover taxes - Stock Titan
After two decades at Alkermes, a biotech CFO joins Tortugas’ board - Stock Titan
Amylyx Pharmaceuticals Inks Avexitide Supply Deals With Bachem and Polypeptide; $30 Million Upfront to Reserve Capacity - TradingView
Amylyx Pharmaceuticals | 8-K: Current report - Moomoo
Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference - Business Wire
Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference - Yahoo Finance
The Manufacturers Life Insurance Company Makes New $679,000 Investment in Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
Amylyx Pharmaceuticals (AMLX) director exercises 50K stock options - Stock Titan
Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%? - Yahoo Finance
Amylyx Pharmaceuticals (AMLX) Is Down 10.1% After Strong Phase 3 Avexitide Data And $500M Equity Raise – Has The Bull Case Changed? - webull.com
Should Eli Lilly Investors Be Worried About a Threat From Amylyx? - Yahoo Finance
Oracle Stock Stands Out Among Healthy High Growth Potential Picks - sahmcapital.com
Oracle Stock And Palantir Shares Stand Out For High Growth Investors - Sahm
Guggenheim Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $57 - Moomoo
Guggenheim raises Amylyx stock price target on financing, trial data By Investing.com - Investing.com Australia
Guggenheim raises Amylyx stock price target on financing, trial data - investing.com
Amylyx Pharmaceuticals (NasdaqGS:AMLX) Stock Forecast & Analyst Predictions - Simply Wall Street
Oracle Stock And Two Other Growth Names With Stronger Balance Sheet Appeal - sahmcapital.com
Rocket Lab Stock Leads 3 High Growth Picks With Fresh Earnings Upside - Sahm
LifeSci Capital Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $44 - Moomoo
Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week - Yahoo Finance
Amylyx (AMLX) Faces a Binary Phase 3 Test. Can Avexitide Rebuild the Company? - Yahoo Finance
MercadoLibre Stock And 2 High Growth Picks With Strong Balance Sheets - Sahm
Amylyx Pharmaceuticals (AMLX) co-CEO nets 60K performance shares - Stock Titan
Amylyx (NASDAQ: AMLX) CMO’s stock award lifts stake to 288,092 shares - Stock Titan
Amylyx Pharmaceuticals Announces Equity Offering to Fund Avexitide - TipRanks
Amylyx Pharmaceuticals Announces $471.7 Million Public Stock Offering Priced at $35.50 Per Share - Kalkine Media
Amylyx Pharmaceuticals Prices 14.09M-Share Public Offering at $35.50; Nets ~$472M - TradingView
Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (AMLX), Moderna (MRNA) and Merck & Company (MRK) - The Globe and Mail
Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock - BioSpace
Amylyx Pharmaceuticals Jumps to Fresh Three-Year High as Avexitide Phase 3 Results Bolster Commercial Path - Vinanet
HC Wainwright Has Strong Forecast for AMLX FY2028 Earnings - MarketBeat
39,241 Shares in Amylyx Pharmaceuticals, Inc. $AMLX Bought by GSA Capital Partners LLP - MarketBeat
Amylyx Pharmaceuticals (AMLX) CEO granted 60K shares - Stock Titan
Amylyx Pharmaceuticals Inc Stock (AMLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Amylyx Pharmaceuticals Inc Stock (AMLX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| GEORGE MILNE | Director |
Oct 05 '26 |
Proposed Sale |
27.79 |
100,000 |
2,779,000 |
0 |
| Klee Justin B. | Co-Chief Executive Officer |
Sep 10 '26 |
Sale |
32.18 |
30,464 |
980,263 |
3,613,056 |
| Cohen Joshua B | Co-Chief Executive Officer |
Sep 10 '26 |
Sale |
32.19 |
30,464 |
980,504 |
3,613,123 |
| FRATES JAMES M | Chief Financial Officer |
Sep 10 '26 |
Sale |
32.36 |
10,810 |
349,821 |
233,625 |
| Klee Justin B. | Officer |
Sep 10 '26 |
Proposed Sale |
32.18 |
30,464 |
980,264 |
0 |
| Frates James M | Officer |
Sep 10 '26 |
Proposed Sale |
32.36 |
10,810 |
349,821 |
0 |
| Bedrosian Camille L | Officer |
Sep 10 '26 |
Proposed Sale |
32.40 |
10,028 |
324,868 |
0 |
| Cohen Joshua B | Officer |
Sep 10 '26 |
Proposed Sale |
32.19 |
30,464 |
980,504 |
0 |
| Mazzariello Gina | Officer |
Sep 10 '26 |
Proposed Sale |
32.46 |
9,536 |
309,506 |
0 |
| Mazzariello Gina | Chief Legal Officer |
Sep 10 '26 |
Sale |
32.46 |
9,536 |
309,506 |
190,838 |
1.24%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):